Gate2Brain

gate2brain.com ↗ ·Barcelona ·Series A

Gate2Brain is a Barcelona-based biotech company developing drugs that cross the blood-brain barrier. Its patented platform uses peptide shuttles that can be attached to small molecules, proteins and antibodies to carry them into the brain. Its lead candidate, G2B-002, targets aggressive brain tumours in children and adults and has Orphan Drug Designation from both the EMA and the FDA. The company was founded in July 2020 as a spin-off of IRB Barcelona, the University of Barcelona and the Sant Joan de Déu Research Institute. It was first funded by Fundación Botín's Mind the Gap programme (€500,000) and Banco Sabadell's BStartup Health (€100,000). It later won a €2.5M EIC Accelerator award, and in June 2026 it raised €7M from Shilpa Biocare, which took a 30.4% stake as part of a strategic alliance.

Founded

2020

Founders

Total funds raised

€7.6M

SectorsBiotech, Drug delivery, Oncology, Rare diseases Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Suggest a correction

Founders

Meritxell Teixidó

Co-founder & CEO

Global models 5

Denali Therapeutics

United States · www.denalitherapeutics.com ↗

Like Gate2Brain, Denali built its own platform (Transport Vehicle) to carry antibodies, enzymes and other drugs across the blood-brain barrier, and runs its own neurology pipeline on it while also partnering it with pharma.

$350MComparable

Korsana Biosciences

United States

Korsana is a venture-backed biotech that attaches a transferrin-receptor brain shuttle to its own drugs to get them into the brain; its lead is an Alzheimer's antibody, while Gate2Brain uses peptide shuttles.

$175MComparable

Manifold Bio

United States · www.manifold.bio ↗

Manifold engineers brain shuttles and makes money both from its own CNS drug programmes and from pharma licensing deals such as its Roche agreement, the same platform-plus-pipeline model as Gate2Brain.

$78MComparable

Aerska

Ireland · www.aerska.com ↗

Aerska is a young European biotech that uses a brain-shuttle platform to deliver RNAi medicines across the blood-brain barrier for its own neurology pipeline, much as Gate2Brain does with peptides.

$60MComparable

Aliada Therapeutics

United States · www.aliadatx.com ↗

Aliada built a platform for crossing the blood-brain barrier through the transferrin and CD98 receptors and attached it to its own Alzheimer's antibody; AbbVie bought it for $1.4B in 2024, which is the exit a platform like Gate2Brain's can aim for.

$33MComparable

In the same niche 67 others

See all in the Start-ups Map →

Highlight Therapeutics

+61 more →

Notes: Most funded first

Investors 3

Open as list →

Fundación Botín

www.fundacionbotin.org

Led Seed 2020 Spain

Sabadell Venture Capital

www.bstartup.com

Led Seed 2020 Spain

Shilpa Biocare

www.vbshilpa.com ↗

Led Series A 2026 India

Funding rounds 3

·3 not counted

Date	Round	Amount	Lead
2026-06-16	Series A (estimated)	€7M	Shilpa Biocare (estimated lead)
2020-12-29	Seed	€100K	BStartup (Banco Sabadell)
2020-07-09	Seed (estimated)	€500K	Fundación Botín (Mind the Gap)

Not counted (3)

Not counted in totals

2025-05-21	Grant	approximately €700K	Lead not disclosed +1 more
2022-12-21	Grant	€2.5M	EIC Accelerator
2021-12-27	Grant	€300K	Lead not disclosed +1 more

News 5

Open as list →

Published	Article
2026-06-18	Gate2Brain: Shilpa Biocare Invests €7 Million To Advance Brain Cancer Therapeutic Candidate ↗ Pulse 2.0 2026-06-18
2026-06-16	Shilpa Biocare invests in Gate2Brain, an IRB Barcelona spin-off, to advance an innovative therapeutic candidate for brain cancer ↗ IRB Barcelona 2026-06-16
2025-06-23	Gate2Brain obtains FDA Orphan Drug Designation for G2B-002 ↗ Catalonia.Health 2025-06-23
2025-05-21	Gate2Brain secures over €700,000 in CDTI Multipaís funding to advance a novel therapy against pediatric brain tumors in collaboration with India ↗ AseBio 2025-05-21
2024-11-20	Gate2Brain Receives EMA Orphan Drug Designation for Its Groundbreaking Pediatric Cancer Treatment ↗ Institut de Recerca Sant Joan de Déu 2024-11-20